Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation

  • STATUS
    Recruiting
  • participants needed
    60
  • sponsor
    The Cleveland Clinic
Send
Updated on 1 February 2023
See if I qualify
ct scan
fever
x-rays
pneumonia
acute respiratory failure
hypoxia
covid-19
chest x-ray
SARS
respiratory failure
acute respiratory syndrome (sars)
mavrilimumab

Summary

The purpose of this prospective, Phase 2, multicenter, blinded, randomized placebo controlled study is to demonstrate that early treatment with mavrilimumab prevents progression of respiratory failure in patients with severe COVID-19 pneumonia and clinical and biological features of hyper-inflammation.

Description

This prospective, Phase 2, multi-center, blinded randomized placebo-controlled study is designed to demonstrate that early treatment with mavrilimumab prevents progression of respiratory failure in patients with severe Covid-19 pneumonia and clinical and biological features of hyper-inflammation.

The study population includes patients who have severe pneumonia, defined as hospitalization due to Covid-19 with abnormal chest imaging and SpO2 <92% on room air or requirement for supplemental oxygen.

Enrollment: The study will be performed in approximately 4 months total, starting from the first patient enrolled with enrollment expected to complete within 2 months.

Follow-up period: The follow-up period is 60 days for each patient enrolled.

A total of 60 patients will be randomized using a 1:1 allocation ratio: 30 subjects will receive mavrilimumab, and 30 subjects will receive placebo infusion. The investigator, clinical team, and subject will be blinded to treatment assignment.

Participants will be identified by regular review of hospitalized COVID19 patients to evaluate for inclusion and exclusion criteria. Participants will then be approached in the standard manner by study investigator and coordinator/research nurse.

Research interventions will take place in the hospital in accordance with privacy standards.

The study team is informed on all study procedures and requirements with daily meetings and the opportunity to continuously update through secure channels.

In this multicenter consortium, each participating site will have their own IND for patients enrolled at their site. Data collection will occur at each of the 4 academic centers, and data analysis and randomization scheme will be performed by one site, Cleveland Clinic C5 Research.

Details
Condition Pulmonary Disease, Upper respiratory infection, Pneumonia, Pneumonia, Covid 19, SARS-CoV 2
Age 18years - 100years
Treatment Placebos, mavrilimumab
Clinical Study IdentifierNCT04399980
SponsorThe Cleveland Clinic
Last Modified on1 February 2023

Eligibility

 Yes No Not Sure

Inclusion Criteria

Written informed consent must be obtained before any assessment is performed
Documented COVID19 pneumonia defined as positive SARS-CoV2 test AND abnormalities/ infiltrates on chest x-ray or computed tomography AND active fever or documented fever within 24-48 hours or ongoing anti-pyretic use to suppress fever
Hypoxia (Room air SpO2 <92% or requirement for supplemental oxygen)
Increased serum inflammatory marker (CRP > 5 mg/dL)
Severity of disease warrants inpatient hospitalization

Exclusion Criteria

Onset of COVID-19 symptoms >14 days
Age < 18 years-old
Hospitalized >7 days
Mechanically ventilated
Serious concomitant illness which in the opinion of the investigator precludes the patient from enrolling in the trial, including (but not limited to)
History of immunodeficiency (congenital or acquired)
Neutropenia (absolute neutrophil count <1,500/mm3)
History of solid-organ or bone marrow transplant
History of current systemic autoimmune or autoinflammatory disease(s) requiring systemic immune-modulating drugs
History of myeloproliferative disorder or active malignancy receiving cytotoxic chemotherapy
Pre-existing severe pulmonary disease (i.e. steroid dependent asthma, COPD on home oxygen, or other restrictive/obstructive lung disease requiring home oxygen)
Pre-existing severe left ventricular systolic dysfunction (i.e. LVEF <35%)
Known or suspected active tuberculosis (TB), latent TB, or history of incompletely treated TB or at high risk for latent TB (from exposure or prior incarceration)
History of active or latent viral hepatitis (i.e. Hepatitis B or C)
Concomitant uncontrolled systemic bacterial or fungal infection
Concomitant viral infection other than COVID-19 (e.g. Influenza, other respiratory viruses)
History of chronic liver disease with portal hypertension
History of end-stage renal disease on chronic renal replacement therapy
Recent treatment with cell-depleting biological therapies (e.g., anti-CD20) within 12 months, cell-depleting biological therapies (such as anti-tumor necrosis factor [TNF], anakinra, anti-Interleukin [IL]-6 receptor [e.g. tocilizumab], or abatacept) within 8 weeks (or 5 half-lives, whichever is longer), treatment with alkylating agents within 12 weeks, treatment with cyclosporine A, azathioprine, cyclophosphamide, or mycophenolate mofetil (MMF) within 4 weeks
Recent treatment with intramuscular live (attenuated) vaccine within 4 weeks
Chronic or recent corticosteroid use > 10 mg/day
Pregnant. Breast-feeding women are eligible with the decision to continue or discontinue breast-feeding during therapy taking into account the risk of infant exposure, the benefits of breast-feeding to the infant, and benefits of treatment to the mother
Enrolled in another investigational study using immunosuppressive therapy
Known hypersensitivity to mavrilimumab or any of its excipients
In the opinion of the investigator, unable to comply with the requirements to participate in the study
Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing of investigational drug. Such methods include
Total abstinence (when this is in line with the preferred and usual lifestyle of the subject). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception
Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or bilateral tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment
Male sterilization (at least 6 months prior to screening). For female subjects on the study, the vasectomized male partner should be the sole partner for that subject
Use of oral, (estrogen and progesterone), injected or implanted hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS), or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

ct scan
fever
x-rays
pneumonia
acute respiratory failure
hypoxia
covid-19
chest x-ray
SARS
respiratory failure
acute respiratory syndrome (sars)
mavrilimumab

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.